Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines

A. Marshall Mcbean, Mary Lou Thoms, Paul Albrecht, Judith C. Cuthie, Roger Bernier

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


In a randomized, controlled trial carried out from November 1980 to July 1983 involving 1,114 infants in Baltimore City and in Baltimore and Prince George's counties, Maryland, the serologic response to three doses of two enhanced-potency inactivated polio vaccines was compared with the response to three doses of oral polio vaccine. The mean ages at vaccination were 2.2, 4.7, and 19.9 months, respectively, for the three doses. Seroconversion after the first dose varied from 35% to 84%, and it was higher after oral polio vaccine than after either of the enhanced-potency inactivated polio vaccines for polioviruses types 2 and 3. Approximately two and one-half and 16 months after the second dose, almost all inactivated polio vaccine recipients had antibodies against all three virus types (98-100%). Fewer oral polio vaccine recipients had detectable antibodies to type 1 (89-92%) and to type 3 (96%). After three doses of vaccine, all children had antibodies against types 2 and 3. Approximately 1% of the inactivated polio vaccine recipients and 3% of the oral polio vaccine recipients lacked antibody to type 1. One or two doses of oral polio vaccine stimulated higher reciprocal geometric mean antibody titers against type 2 poliovirus than did the inactivated polio vaccine. For the other two types, the results were mixed. The third dose of inactivated polio vaccine produced significant increases in the reciprocal geometric mean titers against each of the three poliovirus types and resulted in significantly higher reciprocal geometric mean titers after three doses of vaccine for recipients of inactivated polio vaccine than for recipients of oral polio vaccine.

Original languageEnglish (US)
Pages (from-to)615-628
Number of pages14
JournalAmerican journal of epidemiology
Issue number3
StatePublished - Sep 1988

Bibliographical note

Funding Information:
This research was supported by Centers for Disease Control Contract 210-80-0512 and by Connaught Laboratories Ltd., with the cooperation of the nursing and medical staff of the Baltimore City Health Department, Baltimore County Health Department, Francis Scott Key Medical Center, and Prince George's County Health Department.


  • Poliomyelitis
  • Poliovirus
  • Poliovirus vaccine
  • Serology


Dive into the research topics of 'Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines'. Together they form a unique fingerprint.

Cite this